Literature DB >> 15258008

How do you know?

J T Rosenbaum1, A Deodhar, E B Suhler, J R Smith.   

Abstract

Mesh：

Year:  2004        PMID： 15258008      PMCID： PMC1772291          DOI： 10.1136/bjo.2004.042986

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  17 in total

1.  Alpha4 integrins as therapeutic targets in autoimmune disease.

Authors:  Ulrich H von Andrian; Britta Engelhardt
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

2.  An open study of B lymphocyte depletion in systemic lupus erythematosus.

Authors:  Maria J Leandro; Jonathan C Edwards; Geraldine Cambridge; Michael R Ehrenstein; David A Isenberg
Journal:  Arthritis Rheum       Date:  2002-10

3.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

Authors:  Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass
Journal:  Arch Ophthalmol       Date:  2002-06

4.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

Authors:  R B Nussenblatt; E Fortin; R Schiffman; L Rizzo; J Smith; P Van Veldhuisen; P Sran; A Yaffe; C K Goldman; T A Waldmann; S M Whitcup
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

5.  Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.

Authors:  A Beniaminovitz; S Itescu; K Lietz; M Donovan; E M Burke; B D Groff; N Edwards; D M Mancini
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

6.  High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.

Authors:  Roy W Beck; Jonathan D Trobe; Pamela S Moke; Robin L Gal; Dongyuan Xing; M Tariq Bhatti; Michael C Brodsky; Edward G Buckley; Georgia A Chrousos; James Corbett; Eric Eggenberger; James A Goodwin; Barrett Katz; David I Kaufman; John L Keltner; Mark J Kupersmith; Neil R Miller; Sarkis Nazarian; Silvia Orengo-Nania; Peter J Savino; William T Shults; Craig H Smith; Michael Wall
Journal:  Arch Ophthalmol       Date:  2003-07

Review 7.  An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.

Authors:  Jeffrey M Weinberg
Journal:  Clin Ther       Date:  2003-10       Impact factor: 3.393

8.  Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS report no. 20.

Authors: 
Journal:  Arch Ophthalmol       Date:  2003-08

9.  Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate.

Authors:  C Stephen Foster; Fehma Tufail; Nadia Khalida Waheed; David Chu; Elisabetta Miserocchi; Stefanos Baltatzis; Cindy M Vredeveld
Journal:  Arch Ophthalmol       Date:  2003-04

10.  Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; G Burmester; W Golder; E Gromnica-Ihle; H Kellner; M Schneider; H Sörensen; H Zeidler; J Reddig; J Sieper
Journal:  Arthritis Rheum       Date:  2003-08
View more
  2 in total

1.  Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis.

Authors:  Conor C Murphy; Kathrin Greiner; Jarka Plskova; N Andrew Frost; John V Forrester; Andrew D Dick
Journal:  Br J Ophthalmol       Date:  2006-09-14       Impact factor: 4.638

2.  Metabolomic analysis of human vitreous humor differentiates ocular inflammatory disease.

Authors:  Stephen P Young; Maged Nessim; Francesco Falciani; Victor Trevino; Somnath P Banerjee; Robert A H Scott; Philip I Murray; Graham R Wallace
Journal:  Mol Vis       Date:  2009-06-13       Impact factor: 2.367
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.